Skip to content

10x Genomics, Inc. TXG Research and development expense

Research and development expense at other companies

TEC
Bio-TechneTECH

Other financials

Income statement

See full
Revenue$150.8M-2.6%
Gross profit$106.2M+0.7%
Operating income-$17.0M+56.7%
Net income-$13.5M+60.8%
EPS (diluted)-$0.10+64.3%

Balance sheet

See full
Cash & equivalents$490.3M+30.0%
Total debt$81.4M+1.6%
Total equity$814.3M+15.2%
Total assets$1.0B+12.4%

Cash flow

See full
Operating cash flow$26.1M-24.0%
CapEx$1.6M-15.6%
Free cash flow$24.5M-24.4%

Valuation

See full
Market cap$4.41B+154%

Profitability

See full
Gross margin69.6%+1.2pp
Operating margin-6.1%-2.7pp
Net margin-3.5%-1.6pp
FCF margin19.1%

Returns & leverage

See full
Return on equity-3%-1.4pp
Debt / equity0.1×0.0×
Current ratio5.9×+0.5×

Where this comes from

Reported directly by 10x Genomics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.

The official record: 10x Genomics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about 10x Genomics, Inc.'s research and development expense.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is 10x Genomics, Inc.'s research and development expense?
10x Genomics, Inc. (TXG) reported research and development expense of $56.85M in Q1 2026.
How has 10x Genomics, Inc.'s research and development expense changed year-over-year?
10x Genomics, Inc.'s research and development expense decreased by 11.5% year-over-year, from $64.25M to $56.85M.
What is the long-term trend for 10x Genomics, Inc.'s research and development expense?
Over 4 years (2021 to 2025), 10x Genomics, Inc.'s research and development expense has grown at a 3.0% compound annual growth rate (CAGR), from $211.75M to $238.63M.